(Q43840708)

27 November 2017

Sirolimus in renal transplantation: analysis of safety and efficacy in a nonprotocol conversion group (English)

1 reference

27 November 2017

1 reference

P H F Gois

1

1 reference

27 November 2017

G G Rivelli

series ordinal

2

1 reference

27 November 2017

L M Pereira

series ordinal

3

1 reference

27 November 2017

M Mazzali

series ordinal

4

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

Transplantation Proceedings

27 November 2017

1 reference

27 November 2017

44

1 reference

27 November 2017

8

1 reference

27 November 2017

2348-2351

1 reference

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Chronic allograft nephropathy: An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Strategies to improve long-term outcomes after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Sirolimus: its discovery, biological properties, and mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Sirolimus: defining nephrotoxicity in the renal transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Kidney Transplantation With Sirolimus and Mycophenolate Mofetil???Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Reduced exposure to calcineurin inhibitors in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Proteinuria following a switch from calcineurin inhibitors to sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.010

10.1016/J.TRANSPROCEED.2012.07.010

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference